Print the following instructions

Next Step: Continue to online enrollment form

Please follow the instructions in your T.I.P.S.™ (TIKOSYN In Pharmacy System) kit when filling a TIKOSYN® (dofetilide) prescription. See steps detailed below:

1. Verify prescriber certification status.

2. Order TIKOSYN through your wholesaler.

3. Stamp, sign, and date the back of the prescription upon filling.

In order to expedite the TIKOSYN ordering process, kindly review the information detailed below.

1. Order TIKOSYN through your wholesaler.

2. TIKOSYN orders faxed by your wholesaler are processed during normal Pfizer Customer Service business hours, Monday through Friday 7:00 AM to 5:30 PM CT.

3. Pfizer will verify pharmacy enrollment and drop-ship TIKOSYN to the pharmacy.

Due to the importance of adherence to TIKOSYN therapy once initiated, we recommend you maintain an inventory of TIKOSYN on hand to meet immediate patient needs, especially over weekends or holidays.

Please remember that TIKOSYN may be prescribed only by hospitals and prescribers who have received appropriate TIKOSYN dosing and treatment initiation education through the TIKOSYN Education Distribution Program. Therefore, upon the receipt of a new TIKOSYN prescription, it is important always to verify that the prescriber has participated in the program. To verify a prescriber, please call 1-800-788-7353 or log on to www.tikosynlist.com.

TIKOSYN is indicated for the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. TYKOSIN is indicated for the conversion of atrial fibrillation/atrial flutter to normal sinus rhythm. To minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation. TIKOSYN is available only to hospitals and prescribers who have received appropriate TIKOSYN dosing and treatment initiation education. TIKOSYN can cause serious ventricular arrhythmias, primarily torsades de pointes type ventricular tachycardia, a polymorphic ventricular tachycardia associated with QT interval prolongation. Calculation of creatinine clearance and QTc for all patients must precede administration of the first dose of TIKOSYN. Renal function and QTc should be re-evaluated every 3 months or as medically warranted. TIKOSYN is contraindicated in patients with congenital or acquired long QT syndromes, severe renal impairment, or known hypersensitivity to TIKOSYN. TIKOSYN is also contraindicated with verapamil, hydrochlorothiazide (alone or in combination, such as with triamterene), and cation transport system inhibitors such as cimetidine, ketoconazole, trimethoprim (alone or in combination with sulfamethoxazole), prochlorperazine, and megestrol. The most common adverse events reported with a frequency of >5% were headache, chest pain, dizziness, respiratory tract infection, dyspnea, and nausea.